BioAge Labs (BIOA) EBT Margin (2025 - 2026)
BioAge Labs (BIOA) posted EBT Margin of 801.12% for Q1 2026, down 56.93% sequentially from 510.49% in Q4 2025, and up 9702.0% YoY from 8.17% in Q1 2025.
BioAge Labs (BIOA) EBT Margin (2025 - 2026) Analysis & Trends
BioAge Labs has reported EBT Margin for 2 years, with the latest figure at 801.12% in Q1 2026.
- Quarterly EBT Margin rose 9702.0% year-over-year to 801.12% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 892.11% (up 890548.0% YoY) and the FY2025 annual result came in at 1400.11%, changed N/A from the prior year.
- EBT Margin retreated to 801.12% in Q1 2026 per BIOA's latest filing, from 510.49% in the prior quarter.
- Over five years, EBT Margin peaked at 510.49% in Q4 2025 and troughed at 1390.12% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -10.99% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 35.09% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 13.34% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 47.58% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.70% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 16.91% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 4.09% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | BioAge Labs | 434.04 Mn | 434.04 Mn | -14.23 Mn | -1,056.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6,430.48% |
| Mar 31, 2026 | -801.12% |
| Dec 31, 2025 | -510.49% |
| Sep 30, 2025 | -1,390.12% |
| Jun 30, 2025 | -1,059.58% |
| Mar 31, 2025 | -898.14% |